AGROSPHERES ANNOUNCES NOVEL MODALITIES PARTNERSHIP WITH BAYER

AgroSpheres’ AgriCell technology will help deliver the next generation of high-performing, environmentally safe crop protection

CHARLOTTESVILLE, VA – AgroSpheres, INC., a leader in developing the next generation of environmentally friendly crop protection products, today announced a multi-year collaboration with Bayer to create novel modalities of biologicals for use as crop protection products.

“Teaming up with a leading global partner like Bayer helps us execute a mission we are both passionate about – transforming agriculture with better and more sustainable products for growers,” said Ameer Shakeel, Founder and CTO of AgroSpheres. “This collaboration also brings us one step closer to establishing AgroSpheres as a next-generation biosciences company.”

AgroSpheres’ patented AgriCell manufacturing technology enables the production of encapsulated biomolecules with enhanced stability, field persistence and targeted delivery.

“AgroSpheres’ novel AgriCell systems are innovative technologies that will help us to explore new sustainable crop protection products,” said Rachel Rama, Head of Small Molecules for Bayer. “AgroSpheres’ cutting-edge scientific team will help us as we continue to improve innovative product offerings for our grower customers.”

Biomolecules such as peptides and nucleic acids have demonstrated great promise in the lab but have generally struggled to yield consistent results for commercial biological development. The AgriCell technology fills the missing link in delivering reliable field performance and opening new markets for high-performance biopesticides. Used with novel modalities, AgriCell technology will help deliver biopesticides that:

Outperform traditional biologicals	Are non-toxic to humans and animals
Are durable in the environment	Target specific pests
Help manage resistance

BRAINBox Solutions Announces Publication in JAMA Network OPEN of Major Analysis of Initial HeadSmart II Trial Concussion Patients

BRAINBox Solutions today announced the publication in JAMA Network OPEN of a major analysis of the first 1,000 patients with suspected concussion (mild traumatic brain injury or mTBI) in its pivotal, HeadSMART II study of its initial test, BRAINBox TBI, for concussion diagnosis and prognosis. The analysis, the largest of its kind, identified patient characteristics …

10/16/2025

Phlow Corp. Selected by the U.S. Food and Drug Administration Commissioner’s First-Ever National Priority Voucher Pilot Program to Advance Manufacturing of a Critical Essential Medicine in America

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that the active pharmaceutical ingredient for ketamine will be included in the first-ever U.S. Food and Drug Administration (FDA) Commissioner’s National Priority Voucher (CNPV) Pilot Program. This designation recognizes Phlow’s leadership in advancing domestic manufacturing of essential and life-changing medicines …

10/16/2025

Civica To Launch Long-Acting Insulin Glargine in the US in January 2026

Non-profit pharmaceutical company Civica will launch an affordable long-acting insulin – insulin glargine-yfgn in pre-filled pens – at the lowest list price in the current long-acting insulin market. Civica insulin glargine will be available in the United States beginning January 1, 2026. In California, the product will carry the “CalRx” brand. “Civica will provide insulin …

News